BRPI0409860A - processo de solidificação anti-solvente - Google Patents

processo de solidificação anti-solvente

Info

Publication number
BRPI0409860A
BRPI0409860A BRPI0409860-9A BRPI0409860A BRPI0409860A BR PI0409860 A BRPI0409860 A BR PI0409860A BR PI0409860 A BRPI0409860 A BR PI0409860A BR PI0409860 A BRPI0409860 A BR PI0409860A
Authority
BR
Brazil
Prior art keywords
solidification process
solvent solidification
organic
solvent
solidified
Prior art date
Application number
BRPI0409860-9A
Other languages
English (en)
Inventor
Wridzer Jan Willem Bakker
Robert Michael Geertman
Marianne Frederika Reedijk
Jozef Johannes Maria Baltussen
Gerrald Bargeman
Conelis Elizabeth Johannu Lare
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33418418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409860(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BRPI0409860A publication Critical patent/BRPI0409860A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D3/00—Halides of sodium, potassium or alkali metals in general
    • C01D3/22—Preparation in the form of granules, pieces, or other shaped products
    • C01D3/24—Influencing the crystallisation process
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Abstract

"PROCESSO DE SOLIDIFICAçãO ANTI-SOLVENTE". A presente invenção refere-se a um processo de solidificação anti-solvente, em que um meio líquido, compreendendo pelo menos um composto orgânico ou inorgânico a ser solidificado, é forçado através de uma membrana a se juntarem a um ou mais anti-solventes ou em que um ou mais anti-solventes são forçados através de uma membrana a se juntar a um meio líquido compreendendo pelo menos um composto orgânico ou inorgânico a ser solidificado, produzindo uma composição que compreende partículas sólidas compreendendo o(s) dito(s) composto(s) orgânico(s) e/ou inorgânico(s).
BRPI0409860-9A 2003-04-29 2004-04-28 processo de solidificação anti-solvente BRPI0409860A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46676103P 2003-04-29 2003-04-29
PCT/EP2004/004506 WO2004096405A1 (en) 2003-04-29 2004-04-28 Antisolvent solidification process

Publications (1)

Publication Number Publication Date
BRPI0409860A true BRPI0409860A (pt) 2006-05-16

Family

ID=33418418

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409860-9A BRPI0409860A (pt) 2003-04-29 2004-04-28 processo de solidificação anti-solvente

Country Status (23)

Country Link
US (4) US20060182808A1 (pt)
EP (1) EP1620193B1 (pt)
JP (1) JP5207432B2 (pt)
KR (1) KR20060006949A (pt)
CN (1) CN100434133C (pt)
AR (1) AR044140A1 (pt)
AT (1) ATE406946T1 (pt)
AU (1) AU2004234057A1 (pt)
BR (1) BRPI0409860A (pt)
CA (1) CA2523883C (pt)
CL (1) CL2004000912A1 (pt)
DE (1) DE602004016311D1 (pt)
ES (1) ES2312996T3 (pt)
HK (1) HK1088268A1 (pt)
IL (1) IL171613A (pt)
MX (1) MXPA05011626A (pt)
MY (1) MY141189A (pt)
NO (1) NO20055607D0 (pt)
NZ (1) NZ543772A (pt)
RU (1) RU2339364C2 (pt)
TW (1) TW200500095A (pt)
WO (1) WO2004096405A1 (pt)
ZA (1) ZA200509597B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475845B2 (en) * 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
US7942990B2 (en) 2006-12-18 2011-05-17 Daicel Chemical Industries, Ltd. Hybrid inflator
EP2124633B1 (en) * 2007-01-22 2012-03-07 Cargill, Incorporated Method of producing purified rebaudioside a compositions using solvent/antisolvent crystallization
GB0705159D0 (en) * 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
FI120527B (fi) * 2007-06-18 2009-11-30 Crisolteq Oy Talteenottomenetelmä
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
TWI466709B (zh) * 2011-07-20 2015-01-01 Nat Univ Chung Hsing From the original berry Wolfberry a liquid - liquid freezing method for separation of high purity theaflavins palmitate Maize
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9452930B2 (en) * 2013-11-04 2016-09-27 New Jersey Institute Of Technology System and method for continuous polymer coating of particles
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT108368B (pt) * 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN106853295A (zh) * 2015-12-09 2017-06-16 北大方正集团有限公司 一种基于膜分散的结晶方法
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10881123B2 (en) * 2017-10-27 2021-01-05 Frito-Lay North America, Inc. Crystal morphology for sodium reduction
JP6761560B2 (ja) * 2018-06-14 2020-09-23 日揮株式会社 晶析装置及び晶析方法
CN112969466A (zh) * 2018-12-28 2021-06-15 四川科伦药物研究院有限公司 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂
CN111234431A (zh) * 2020-03-31 2020-06-05 宁夏颐星新材料科技有限公司 一种消泡型聚乙烯醇粉末的生产工艺
GB202004824D0 (en) * 2020-04-01 2020-05-13 Naturbeads Ltd Biopolymer particle preparation
GB202011836D0 (en) 2020-07-30 2020-09-16 Micropore Tech Limited Crystallisation methods
CN115777906A (zh) * 2021-09-10 2023-03-14 吉林大学 氯化钠纳微米粒子及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716453B1 (fr) * 1994-02-22 1996-03-29 Rhone Poulenc Agrochimie Procédé de sulfinylation de composés hétérocycliques.
US4089843A (en) * 1976-09-20 1978-05-16 The Upjohn Company Precipitating polymers in powder form
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
JPH0672528B2 (ja) * 1985-07-16 1994-09-14 三信工業株式会社 船舶のエンジン
US5269926A (en) * 1991-09-09 1993-12-14 Wisconsin Alumni Research Foundation Supported microporous ceramic membranes
FR2658498B1 (fr) * 1990-02-19 1992-05-15 Atochem Particules de chlorure de magnesium a structure tronc conique, composante catalytique supportee sur ces particules, polyolefines obtenues a partir de cette composante catalytique, procedes de fabrication de ces produits.
JP2555475B2 (ja) * 1990-10-16 1996-11-20 工業技術院長 無機質微小球体の製造方法
JP2816597B2 (ja) * 1990-11-28 1998-10-27 富士写真フイルム株式会社 溶液の均一混合装置および弾性体多孔膜
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive
WO1993000156A1 (en) * 1991-06-29 1993-01-07 Miyazaki-Ken Monodisperse single and double emulsions and production thereof
EP0617612B1 (en) * 1991-12-18 1997-09-10 Warner-Lambert Company A process for the preparation of a solid dispersion
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
CA2175814C (en) * 1993-11-08 2000-01-04 Stephane Fabrice Rouanet Antiperspirants containing aerogel particles
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
US6387399B1 (en) * 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5876480A (en) * 1996-02-20 1999-03-02 The United States Of America As Represented By The Secretary Of The Navy Synthesis of unagglomerated metal nano-particles at membrane interfaces
GB9610955D0 (en) * 1996-05-24 1996-07-31 Hercules Inc Sizing composition
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
DK1071402T3 (da) * 1998-04-09 2007-02-19 Hoffmann La Roche Fremgangsmåde til af partikler med (sub)mikronstörrelse ved oplösning i komprimeret gas og overfladeaktive stoffer
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
US6113795A (en) * 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN191236B (pt) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6780507B2 (en) * 2000-02-09 2004-08-24 Analytical Research Systems, Inc. Hydrocapsules and method of preparation thereof
US6623761B2 (en) * 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
ATE336231T1 (de) * 2001-08-29 2006-09-15 Dow Global Technologies Inc Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
RS29104A (en) * 2001-10-10 2006-12-15 Boehringer Ingelheim Pharmaceuticals Inc. Powder processing with pressurized gaseous fluids
US6890592B2 (en) * 2002-03-13 2005-05-10 Appleton Papers Inc. Uniform microcapsules
US6966990B2 (en) * 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing

Also Published As

Publication number Publication date
NZ543772A (en) 2009-05-31
CA2523883A1 (en) 2004-11-11
CA2523883C (en) 2012-01-03
RU2005136983A (ru) 2006-03-20
EP1620193B1 (en) 2008-09-03
US20060182808A1 (en) 2006-08-17
MY141189A (en) 2010-03-31
AU2004234057A1 (en) 2004-11-11
CN100434133C (zh) 2008-11-19
MXPA05011626A (es) 2006-01-23
TW200500095A (en) 2005-01-01
IL171613A (en) 2010-02-17
RU2339364C2 (ru) 2008-11-27
US20120232296A1 (en) 2012-09-13
CL2004000912A1 (es) 2005-02-04
US20110268806A1 (en) 2011-11-03
US20130131029A1 (en) 2013-05-23
NO20055607L (no) 2005-11-28
CN1780670A (zh) 2006-05-31
JP2006524565A (ja) 2006-11-02
ATE406946T1 (de) 2008-09-15
AR044140A1 (es) 2005-08-24
ES2312996T3 (es) 2009-03-01
HK1088268A1 (en) 2006-11-03
DE602004016311D1 (de) 2008-10-16
KR20060006949A (ko) 2006-01-20
EP1620193A1 (en) 2006-02-01
JP5207432B2 (ja) 2013-06-12
WO2004096405A1 (en) 2004-11-11
ZA200509597B (en) 2006-12-27
NO20055607D0 (no) 2005-11-28

Similar Documents

Publication Publication Date Title
BRPI0409860A (pt) processo de solidificação anti-solvente
CU23337B7 (es) Resolución de sal quiral
BR0309947A (pt) Processo para a produção de camadas de polìmero
DE69919775D1 (de) Zusammensetzungen aus Ton und organischen chemischen Substanzen zur Herstellung von Nanoverbundstoffen sowie Nanoverbundstoffe ,die diese Zusammensetzungen enthalten
BRPI0412321A (pt) limpeza de membranas de filtração com peróxidos
BR0116022A (pt) Processo para recuperar um composto diidróxi a partir de uma corrente de fluido
ATE168373T1 (de) Benzofuranyl- und thiophenylalkancarbonsäurederivate
DE60321318D1 (de) Gewinnung von delta-9 tetrahydrocannabinol
TW200642828A (en) Method for preparing a microporous polyolefin membrane and the microporous polyolefin membrane
BR9914664A (pt) Membrana composta de zeólito e método para a sua produção
BR0015202A (pt) Processo para a purificação de uma solução contendo aminoácido por meio de eletrodiálise, e processo integrado para a produção de um aminoácido livre
BR0205095A (pt) Aparelho de processamento de sinal para processar fluxos de dados de um tipo de fluxo, e, método de aplicar recurso de reprodução e/ou edição a dados de sinal de fluxo de dados original de um tipo de fluxo
BRPI0416534A (pt) composições multiparticuladas com estabilidade melhorada
BRPI0401103A (pt) Composição compósita, método para formar a mesma, composição modificada, e, método para formar a mesma
DE60008508D1 (de) Agglomerate durch kristallisation
BRPI0400375B8 (pt) processo para remover vírus em soluções de fibrinogênio para aplicação terapêutica
TW200714688A (en) Method for regenerating fluorescent material and fluorescent lamp
BR9714066A (pt) Processo para a preparação de derivados de tiazol.
SE9301789L (sv) Anordning vid bropelare
BR9714005A (pt) Dispositivo de válvula de amortecimento
BR9808011A (pt) Processo para a purificação de caprolactama
BR0307300A (pt) Integração de pelo menos dois processos para reutilizar ácido
BR0305430A (pt) Dormente de dois ou mais blocos e processo para sua fabricação
BR9902349A (pt) Distribuidor para meios, bem como processo para produção de um distribuidor.
BR9917467A (pt) Processos para a polimerização e para reduzir a carga eletrostática na polimerização de uma olefina e/ ou uma olefina e pelo menos uma ou mais outra(s) olefina(s), filme, e, artigo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: N.V. ORGANON (NL)

Free format text: TRANSFERIDO DE: AKZO NOBEL N.V.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.